Market Overview

PHH Corp's Long Runway To Regaining Profitability Keeps Morgan Stanley On The Sidelines, Says Stock Reaction To Regulatory Upside Is Likely Overdone

Share:

Morgan Stanley Lowers Its PT On PHH To $22 From $29, Maintains Equl-Weight

Latest Ratings for PHH

DateFirmActionFromTo
Jun 2017DowngradesOutperformNeutral
Mar 2017UpgradesNeutralOutperform
Oct 2016Initiates Coverage OnNeutral

View More Analyst Ratings for PHH
View the Latest Analyst Ratings

Posted-In: Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (PHH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
PBHTD SecuritiesMaintains100.0
BEP.PR.ETD SecuritiesDowngrades45.0
CTEKBenchmarkMaintains5.0
IPHIDA DavidsonReiterates84.0
JYNTDA DavidsonMaintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

La Jolla Pharma Is A 'Top Pick' For This Analyst

No Longer A Buy: Roth Capital Downgrades Keryx Biopharma, Slashes Price Target To $6